跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RIABNI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RIABNI
Authorized
STANDARD
RIABNI
Amgen Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
1225d7dad92bed4f
Company
Amgen Canada Inc
Type
Standard
Approval Details
Approval Id
1225d7dad92bed4f
Drug Approval Canada Name
RIABNI
Product Name
RIABNI
Status
Cancelled Post Market
Status Date
2024-10-10
Original Market Date
2021-04-21
Din
02513447
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FA01 RITUXIMAB
Atc Name
l 01 fa 01
Aig Number
0140241001
Company Name
Amgen Canada Inc
Company Address
300, 6775 Financial Drive, Mississauga, Ontario, Canada, L5N 0A4
Active Ingredients
RITUXIMAB
10 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
1225d7dad92bed4f
Type
Standard
Back to Health Canada Approvals